DOCSLIB.ORG

N-Acetylcysteine and Sodium 2-Mercaptoethane Sulfonate As Sources of Urinary Thiol Groups in the Rat1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
N-Acetylcysteine and Sodium 2-Mercaptoethane Sulfonate As Sources of Urinary Thiol Groups in the Rat1 [CANCER RESEARCH 44, 3797-3800, September 1984] N-Acetylcysteine and Sodium 2-Mercaptoethane Sulfonate as Sources of Urinary Thiol Groups in the Rat1 Kari Ormstad2 and Yasuo Ohno Department of Forensic Medicine, Karolinska Inst/tutet. S-104 01 Stockholm. Sweden ABSTRACT Cells of various organs were isolated according to techniques routinely used in our laboratory; hepatocytes as described by Moldéuset al. (13), Increasing the urinary output of free thiol groups protects kidney cells according to the data of Jones ef al. (10), intestinal epithelial against cyclophosphamide-induced bladder toxicity. In the pres cells according to the data of Dawson and Bridges (8), myocardial cells ent study, intact rats, isolated perfused kidneys, and freshly according to the data of Rajs et al. (19), and pulmonary cells according isolated cells from various rat organs are used to compare the to the data of Dawson et al. (9). In vitro perfusion of isolated kidneys efficacy of A/-acetylcysteine and sodium 2-mercaptoethane sul- was performed as described by Ormstad ef al. (15), and urine was collected from ureteral catheters. fonate (mesna) as sources of urinary thiols. For the in vivo experiments, rats were anesthetized with diethyl ether. In intact rats given a single i.v. dose of mesna, urinary thiol Via a small abdominal incision, a silicone catheter was inserted in the output is approximately 10-fold higher than in rats given an urinary bladder and secured with a ligature, and the urethra was closed equimolar dose of /V-acetylcysteine. This is partly due to the fact immediately below the neck of the bladder. In the left femoral vein, 16 that A/-acetylcysteine is rapidly absorbed by various types of i/mol Of W-acetylcysteme (16 mw; 1 ml) or 8 ^mol of dimesna (8 ITIM; 1 cells, whereas mesna is transported selectively to the kidney, ml) were injected; similarly treated and operated rats which had been and partly to different renal handling of the two compounds. The given i.v. injections of 1 ml of 0.9% NaCI served as controls. To prevent results suggest that mesna is a more favorable drug than A/- hypoperfusion and pollakisuria during the experiment, 10 ml of 0.9% acetylcysteine for increasing urinary thiol excretion. NaCI were injected s.c. at the nape of the neck of all rats. The rats were placed in stainless steel restriction cages, and urine was sampled in 10- min batches, immediately mixed with an equal volume of 6.5% trichlo- INTRODUCTION roacetic acid, and stored on ice for up to 2 hr, whereupon the content of free thiol groups was determined according to the spectrophotometric Oxazaphosphorine compounds (cyclophosphamide, ifosfam- method of Saville (20). ide, and trofosfamide) are frequently used as cytostatics in All in vitro incubations were performed in a medium consisting of a cancer chemotherapy and as immunosuppressants in organ modified Krebs-Henseieit bicarbonate buffer, pH 7.4, supplemented with transplant recipients and in various states of immunological 25 mw 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid in rotating derangement. Among other side effects, a frequently arising round-bottomed, siliconized glass flasks at 37°under continuous gassing problem during this treatment is hemorrhagic cystitis, which has with carbogen (95% O2 plus 5% CO2). Samples were removed at preset been attributed to the reactive aldehyde, acrolein (CH;>=CH— time points and, in the case of cell incubations designed to study thiol CHO), a product of Oxazaphosphorine metabolism (6,7). Several oxidation, the cells were sedimented by centrifugation (700 rpm for 1 min) before the supernatant was further processed. Cellular uptake of studies have indicated that compounds which are excreted in a mesna, dimesna, and W-acetylcysteine was determined by incubation of form featuring free thiol groups may counteract the urotoxic isolated cells with the compounds in question, separation of the cells effect of oxazaphosphorines (4, 5, 11), and among these A/- acetylcysteine and mesna3 seem to be most effective. In a recent from the medium by rapid centrifugation in a microfuge, and washing once with fresh medium. Free thiols were determined after deproteini- paper, Berrigan ef al. (2) reported that the latter compounds, if zation by addition of an equal volume of 6.5% trichloroacetic acid given in appropriate doses, are equally effective in protecting according to the spectrophotometric method of Saville (20). against cyclophosphamide-induced urothelial damage and Mesna and dimesna were generously supplied by Asta-Werke AG, depression of hepatic drug metabolism. Degussa Pharma Gruppe, Bielefeld, German Federal Republic. All other Since oxazaphosphorine-derived acrolein, which exerts its chemicals were of at least reagent grade and were purchased from local toxicity on the lining of the urinary passages, is likely to be commercial sources. produced after glomerular filtration (21), the potency of a uropro- tective drug is dependent on its capacity to yield free thiol groups RESULTS in the urine. The aim of the present study was to compare A/- In contrast to previous findings with mesna (17), the sponta acetylcysteine and mesna as sources of urinary thiols in the rat. neous rate of oxidation of A/-acetylcysteine was very slow in the absence of biological material (Chart 1). Neither did addition of MATERIALS AND METHODS citrated plasma to the incubation affect the oxidation rate. Incu bation with isolated cells from rat intestine or kidney did, how Male Sprague-Dawley rats weighing 200 to 300 g were kept in ever, lead to oxidation of A/-acetylcysteine to the corresponding stainless steel cages with free access to tap water and pelleted rat food. disulfide; about twice as rapidly in the presence of renal cells as with intestinal cells. Incubations were also performed with iso 'This work was funded by the Swedish Board for Technical Development and lated hepatocytes and pulmonary cells, but with these cells the by the Swedish Medical Research Council, Grant 03X 2471. "To whom requests for reprints should be addressed, at Department of Forensic oxidation rate did not differ from that observed in the absence Mediane, Karolinska Institute!. Box 60400, S-104 01 Stockholm, Sweden. 3The abbreviations used are: mesna, sodium 2-mercaptoethane sulfonate; di- of cells in the incubation (data not shown). Based upon these mesna, sodium 2-mercaptoethane sulfonate disulfìde;SH, sulthydryl results and upon those of Bonanomi and Gazzaniga (3), we Received September 28,1983; accepted June 4,1984. chose to perform the following comparative experiments with SEPTEMBER 1984 3797 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 1984 American Association for Cancer Research. K. Ormstad and Y. Ohno cysteine. After 100 min, approximately 27% of the dimesna injected was excreted in thiol form, whereas only approximately 3% of the A/-acetylcysteine had reached the urine as free thiol. According to previous experience, dimesna does not penetrate into most living tissues, and in a series of experiments, we compared uptake rates for radiolabeled mesna, dimesna, and A/- acetylcysteine into freshly isolated cells from various rat organs (Table 1). Among the cell types tested, only renal and intestinal epithelial cells absorbed mesna or dimesna to any substantial degree, whereas N-acetylcysteine was readily absorbed by all cell types. These data suggest that the discrepancy between dimesna and N-acetylcysteine as source of urinary thiol observed in the in vivo experiments may at least partly be due to the fact 20 40 60 that N-acetylcysteine is retained in various tissues and enters time (min) various metabolic pathways, thus being prevented from ever Chart 1. Oxidation of N-acetylcysteine to the corresponding disulfide during reaching the kidneys. incubation in vitro at 37° under a carbogen (95% O¡,5% CO2) atmosphere. Incubation media contained Krebs-Henseleit bicarbonate buffer, pH 7.4 (O), human However, different renal handling of the 2 compounds may citrated plasma (A), intestinal epithelial cells (10* cells/ml) in Krebs-Henseleit buffer also contribute to the observations presented in Charts 2 and 3. (•),andrenal epithelial cells (10* cells/ml) in Krebs-Henseleit buffer (•).Bars,mean To eliminate the influence of other cells and tissues, a series of ±S.D. of 3 separate incubations. experiments was performed where equimolar (in SH units) con centrations of dimesna (200 n»)and N-acetylcysteine (400 ¿¿M) were added to the perfusate circulating through isolated rat kidneys in vitro. Urine was collected in 5-min batches from ureteral catheters, and thiol excretion was monitored (Chart 4). Like in the in vivo situation, dimesna was the most effective thiol source, but the difference was less pronounced. Furthermore, even urine from kidneys perfused with a medium without any B 20 60 t i me (min) _ 2- Chart 2. Urinary concentration of thiol groups in rats given i.v. injections of 8 E /¿molofdimesna (O), 16 nmol of N-acetylcysteine (D). or 15.4 ^mol of NaCI (A). mesna in disulfide form (dimesna) and N-acetylcysteine in thiol Õ form. Urines from mammals normally contain a certain amount of 20 50 100 free thiol groups, mainly originating from cysteine moieties in time ( min ) peptides and other low-molecular-weight compounds. Upon in Chart 3. Urinary excretion of free thiol groups in intact rats given i.v. injections jection of NaCI immediately prior to urine collection, a low and of 8 /¿molofdimesna (O), 16 umol of N-acetylcysteine (HI), or 15.4 «molof NaCI (A). A. accumulated diuresis; B, accumulated amount of free thiol groups in urine. seemingly constant urinary concentration of thiol groups was One experiment typical of 3. found (Chart 2). In rats given injections of A/-acetylcysteine, the urinary thiol concentration was roughly doubled, whereas urine Table 1 from rats given injections of dimesna contained a thiol concen Uptake of mesna, dimesna, and N-acetylcysteine into freshly isolated cells from tration which initially was more than 10-fold higher than under various rat organs Cells (10* cells/ml) were incubated with the sulfur compounds at a 100 ¡atfinal control conditions.
Load more

Recommended publications
  • Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease
    Pediatric Pulmonology 42:989–1001 (2007) State of the Art Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease. A Review of the Literature 1 1 1,2 Ruben Boogaard, MD, * Johan C. de Jongste, MD, PhD, and Peter J.F.M. Merkus, MD, PhD Summary. Mucoactive agents are used to treat a variety of lung diseases involving impaired mucociliary clearance or mucus hypersecretion. The mucoactive agents studied most frequently are N-acetylcysteine (NAC), recombinant human DNase (rhDNase), and hypertonic saline. Studies on the efficacy of these have been mainly conducted in adults, and in patients with cystic fibrosis (CF). The exact role of mucoactive agents in children with non-CF lung disease is not well established. We present an overview of the current literature reporting clinical outcome measures of treatment with NAC, rhDNase, and hypertonic saline in children. Pediatr Pulmonol. 2007; 42:989–1001. ß 2007 Wiley-Liss, Inc. Key words: mucolytic; sulfhydryl compounds; N-acetylcysteine; dornase alfa; hyper- tonic saline; respiratory tract disease. INTRODUCTION One possible means to evaluate a mucoactive agent is to assess its effect on mucociliary clearance (MCC) or cough Mucus clearance is an important primary innate airway clearance with the use of radiolabeled aerosol. Discussing defense mechanism, and our understanding of the key this subject is outside the scope of this review. Moreover, parameters underlying its function has grown rapidly in the studies on mucoactive agents in CF patients, and studies last decade.1,2 Impaired mucus clearance or mucus hyper- on physiotherapy or secretion clearance techniques in secretion are important clinical features in diseases such as (pediatric) lung disease patients have been reviewed by cystic fibrosis (CF), recurrent bronchitis, asthma, and others, and will therefore not be discussed in this review.
    [Show full text]
  • Supportive Care Medications
    th Clinical Pharmacy Guide: Cancer Drug Treatment Assessment and Review 5 Edition Supportive Care Medications Contents Introduction ................................................................................................................. 2 Supportive Care Information in Protocols .................................................................... 2 Antidiarrheals .............................................................................................................. 5 Loperamide ............................................................................................................. 5 Antiemetics .................................................................................................................. 6 Emetogenicity .......................................................................................................... 7 Types of Chemotherapy-Induced Nausea and Vomiting .......................................... 7 Classifications of Antiemetics .................................................................................. 8 Anti-infective Agents .................................................................................................. 10 Antibiotics .............................................................................................................. 10 Antivirals ................................................................................................................ 11 Arthralgias/Myalgias .................................................................................................
    [Show full text]
  • Table III: 2019 Medicare Drug Fee Schedule* CY 2019 4Th Quarter
    Table III: 2019 Medicare Drug Fee Schedule* CY 2019 4th Quarter Average Sales Price (ASP) Data Plus 6 Percent *The Medicare payments allowance limits are effective Oct. 1 through Dec. 31, 2019. CY 2019 CY 2019 CY 2019 CY 2019 Effective Jan. 1 Effective Apr. 1 Effective July 1 Effective Oct. 1 Through Mar. 31 Through June 30 Throught Sept. 30 Through Dec. 31 Code Description Code Dosage ASP plus 6 percent ASP Plus 6 percent ASP Plus 6 percent ASP plus 6 percent J0129 Abatacept 10mg $51.61 $52.49 $53.94 $54.32 J0130 Abciximab injection 10mg $1,429.07 $1,429.07 $1,429.07 $1,429.07 J0133 Acyclovir, 5 mg 5mg $0.05 $0.05 $0.04 $0.04 J0171 Adrenalin epinephrin inject 0.1mg $0.74 $0.76 $0.86 $0.83 J0207 Amifostine 500mg $979.75 $990.39 $977.31 $1,003.59 J0256 Alpha 1 proteinase inhibitor 10mg $4.55 $4.56 $4.51 $4.55 J0280 Aminophyllin 250 MG inj 250mg $7.02 $7.33 $7.33 $10.88 J0289 Amphotericin b liposome inj 10mg $22.19 $23.92 $18.32 $26.09 J0295 Ampicillin sodium per 1.5 gm 1.5gm $2.62 $2.81 $3.32 $2.06 J0360 Hydralazine hcl injection 20mg $2.58 $2.58 $4.07 $4.21 J0456 Azithromycin 500mg $2.76 $2.58 $2.75 $3.05 J0461 Atropine sulfate injection 0.01mg $0.07 $0.07 $0.07 $0.06 J0475 Baclofen 10 MG injection 10mg $169.75 $174.19 $173.39 $169.51 J0476 Baclofen intrathecal trial 50mcg $44.35 $49.98 $50.44 $50.05 J0480 Basiliximab 20mg $3,677.61 $3,687.17 $3,789.63 $3,799.93 J0490 Belimumab 10mg $44.16 $44.16 $44.82 $44.82 J0500 Dicyclomine injection 20mg $69.65 $82.33 $69.97 $57.58 J0515 Inj benztropine mesylate 1mg $18.67 $18.75 $19.89 $17.74 J0570
    [Show full text]
  • Mucoactive Agents for Airway Mucus Hypersecretory Diseases
    Mucoactive Agents for Airway Mucus Hypersecretory Diseases Duncan F Rogers PhD FIBiol Introduction Sputum Profile of Airway Inflammation and Mucus Hypersecretory Phenotype in Asthma, COPD, and CF Which Aspect of Airway Mucus Hypersecretion to Target? Theoretical Requirements for Effective Therapy of Airway Mucus Hypersecretion Current Recommendations for Clinical Use of Mucolytic Drugs Mucoactive Drugs N-Acetylcysteine: How Does it Work? Does it Work? Dornase Alfa Hypertonic Saline Surfactant Analysis Summary Airway mucus hypersecretion is a feature of a number of severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). However, each disease has a different airway inflammatory response, with consequent, and presumably linked, mucus hypersecretory phenotype. Thus, it is possible that optimal treatment of the mucus hyper- secretory element of each disease should be disease-specific. Nevertheless, mucoactive drugs are a longstanding and popular therapeutic option, and numerous compounds (eg, N-acetylcysteine, erdosteine, and ambroxol) are available for clinical use worldwide. However, rational recommen- dation of these drugs in guidelines for management of asthma, COPD, or CF has been hampered by lack of information from well-designed clinical trials. In addition, the mechanism of action of most of these drugs is unknown. Consequently, although it is possible to categorize them according to putative mechanisms of action, as expectorants (aid and/or induce cough), mucolytics (thin
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Mesna Injection
    AF 35421 Format 131401 #037B Size: 8.0” x 10.0” (Flat) 1.0” x 5.0” (Folded) PMS Black 03/20/13 Head to Head MSN-P01 Controlled Studies MESNA INJECTION FUKUOKA** 31%(14/46) 6% (3/46) Rx ONLY SCHEEF** 100% (7/7) 0% (0/8) *Ifosafamide dose 1.2 g/m2 d x 5 DESCRIPTION **Ifosfamide dose 2 to 4 g/m2 d x 3 to 5 Mesna Injection is a detoxifying agent to inhibit the hemorrhagic cystitis induced by ifosfamide. The active ingredient mesna is a synthetic INDICATIONS AND USAGE sulfhydryl compound designated as sodium-2-mercaptoethane sulfonate with a molecular formula of C H NaO S and a molecular weight 2 5 3 2 Mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. of 164.18. Its structural formula is as follows: – + CONTRAINDICATIONS HS-CH2-CH2SO3 Na Mesna is contraindicated in patients known to be hypersensitive to mesna or other thiol compounds. Mesna Injection is a sterile, nonpyrogenic, aqueous solution of clear and colorless to light pink appearance in clear glass multidose vials WARNINGS for intravenous administration. Mesna Injection contains 100 mg/mL mesna, 0.25 mg/mL edetate disodium and sodium hydroxide and/ or hydrochloric acid for pH adjustment. Mesna Injection multidose vials also contain 10.4 mg of benzyl alcohol as a preservative. The Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with solution has a pH range of 6.5 to 7.3. autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions.
    [Show full text]
  • Mesna: Drug Information
    Official reprint from UpToDate® www.uptodate.com ©2017 UpToDate® Mesna: Drug information Copyright 1978-2017 Lexicomp, Inc. All rights reserved. (For additional information see "Mesna: Patient drug information" and see "Mesna: Pediatric drug information") For abbreviations and symbols that may be used in Lexicomp (show table) Brand Names: US Mesnex Brand Names: Canada Mesna for injection; Uromitexan Pharmacologic Category Antidote; Chemoprotective Agent Dosing: Adult Note: Mesna dosing schedule should be repeated each day ifosfamide is received. If ifosfamide dose is adjusted (decreased or increased), the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio. Prevention of ifosfamide-induced hemorrhagic cystitis: Standard-dose ifosfamide (manufacturer’s labeling): IV: Mesna dose is equal to 20% of the ifosfamide dose given for 3 doses: With the ifosfamide dose, hour 4, and at hour 8 after the ifosfamide dose (total daily mesna dose is 60% of the ifosfamide dose) Oral mesna (following IV mesna; for ifosfamide doses ≤2 g/m2/day): Mesna dose (IV) is equal to 20% of the ifosfamide dose at hour 0, followed by mesna dose (orally) equal to 40% of the ifosfamide dose given 2 and 6 hours after the ifosfamide dose (total daily mesna dose is 100% of the ifosfamide dose). Note: If the oral mesna dose is vomited within 2 hours of administration, repeat the dose or administer IV mesna. Short infusion standard-dose ifosfamide (<2.5 g/m2/day): ASCO guidelines: IV: Total mesna dose is equal to 60% of the ifosfamide dose, in 3 divided
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Clinical Protocol CA180372
    Page: 1 Protocol Number: CA180372 IND Number: 66,971 Ex-US Non-IND EUDRACT Number 2011-001123-20 Date: 01-Jun-2011 Revised Date: 28-Oct-2013 Clinical Protocol CA180372 A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Revised Protocol Number: 05 Incorporates Amendment 04 Study Director Medical Monitor M. Brigid Bradley-Garelik, MD Co-Principal Investigator Co-Principal Investigator 24-hr Emergency Telephone Number Bristol-Myers Squibb Research and Development Approved v 7.0 930051415 7.0 Clinical Protocol CA180372 BMS-354825 Dasatinib This document is the confidential and proprietary information of Bristol-Myers Squibb Company and its global affiliates (BMS). By reviewing this document, you agree to keep it confidential and to use and disclose it solely for the purpose of assessing whether your organization will participate in and/or the performance of the proposed BMS-sponsored study. Any permitted disclosures will be made only on a confidential "need to know" basis within your organization or to your independent ethics committee(s). Any other use, copying, disclosure or dissemination of this information is strictly prohibited unless expressly authorized in writing by BMS. Any supplemental information (eg, amendments) that may be added to this document is also confidential and proprietary to BMS and must be kept in confidence in the same manner as the contents of this document. Any person who receives this document without due authorization from BMS is requested to return it to BMS or promptly destroy it. All other rights reserved.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: a Scoping Review
    antioxidants Review Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: A Scoping Review Omar Cauli 1,2 1 Frailty and Cognitive Impairment Group (FROG), University of Valencia, 46010 Valencia, Spain; [email protected]; Tel.: +34-96-386-41-82; Fax: +34-96-398-30-35 2 Department of Nursing, University of Valencia, 46010 Valencia, Spain Abstract: Cognitive impairment is one of the most deleterious effects of chemotherapy treatment in cancer patients, and this problem sometimes remains even after chemotherapy ends. Common classes of chemotherapy-based regimens such as anthracyclines, taxanes, and platinum derivatives can induce both oxidative stress in the blood and in the brain, and these effects can be reproduced in neuronal and glia cell cultures. In rodent models, both the acute and repeated administration of doxorubicin or adriamycin (anthracyclines) or cisplatin impairs cognitive functions, as shown by their diminished performance in different learning and memory behavioural tasks. Administration of compounds with strong antioxidant effects such as N-acetylcysteine, gamma-glutamyl cysteine ethyl ester, polydatin, caffeic acid phenethyl ester, and 2-mercaptoethane sulfonate sodium (MESNA) counteract both oxidative stress and cognitive alterations induced by chemotherapeutic drugs. These antioxidant molecules provide the scientific basis to design clinical trials in patients with the aim of reducing the oxidative stress and cognitive alterations, among other probable central nervous system changes, elicited by chemotherapy in cancer patients. In particular, N-acetylcysteine and MESNA are currently used in clinical settings and are therefore attracting scientific attention. Citation: Cauli, O. Oxidative Stress and Cognitive Alterations Induced by Keywords: taxanes; anthracyclines; platinum; cognition; biomarker; N-acetylcysteine; clinical trial Cancer Chemotherapy Drugs: A Scoping Review.
    [Show full text]